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ABSTRACT 
Eosinophils are multifunctional leukocytes implicated in the pathogenesis of 
inflammatory processes including hypereosinophilic syndrome, eosinophilic esophagitis, 
and allergic asthma. Due to its role in the initiation and propagation of inflammatory 
responses, and as modulators between innate and adaptive immunity, eosinophils are 
emerging as critical cells in both health and disease. Eosinophil activation and 
inflammatory signaling are dependent on interleukin-5 (IL-5) and signaling by its 
receptor, IL-5R, comprised of a ligand specific alpha chain (IL-5Rα) and a shared 
signaling component, βc. Previously, our laboratory demonstrated the critical role of 
three membrane proximal lysine residues in the cytoplasmic domain of βc for Janus 
kinase (JAK) binding and optimal receptor ubiquitination, and such binding is 
responsible for receptor signaling and endocytosis following IL-5 stimulation. However, 
little is known about whether or not IL-5Rα itself is ubiquitinated or what the molecular 
determinants are. Since βc and IL-5Rα are both members of the Type I cytokine receptor 
family, with similar structural features, we hypothesized that IL-5Rα is also 
ubiquitinated and that lysine residues in homologous regions were important for this 
process.  
To test this hypothesis, we performed site directed mutagenesis on four 
membrane proximal lysine residues within the cytoplasmic domain of IL-5Rα, 
generating six mutant receptors expressed in HEK293 cell lines with wild-type βc. Our 
data revealed that IL-5Rα is ubiquitinated under steady state conditions, highlighting a 
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novel role of ubiquitin in stabilizing cell surface expression of receptors prior to cytokine 
stimulation. In addition, the binding of JAKs to IL-5Rα depended on the presence of all 
four lysine residues, and such binding resulted in optimal ubiquitination under basal 
conditions. Our most striking finding was the IL-5-induced deubiquitination of IL-5Rα 
that triggers receptor internalization, with this deubiquitination event being dependent on 
the presence of the third and fourth lysine residues (Lys370 and Lys379).  
 In sum, these findings reveal a unique regulatory role for ubiquitin in IL-5Rα 
biology, particularly the significance of receptor deubiquitination following cytokine 
stimulation. Due to the specific role of IL-5Rα within eosinophil biology, results from 
this study may provide more insight into IL-5Rα regulation and perhaps help identify 
novel molecular targets for controlling inappropriate signaling associated with 
eosinophilic inflammation.  
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INTRODUCTION 
 
Introduction and Background  
 Eosinophils are leukocytes of the innate immune system characterized by their 
bi-lobed nuclei and ‘brick-red’ coloring following eosin-staining(1). Historically, 
eosinophils have long been recognized for their cytotoxic, effector function in defense 
against parasitic infection(2), with recent studies documenting additional host defense 
against viruses(3,4), fungi(5-7), and bacteria(8). Recently, great strides have been made in 
eosinophil biology, widening its role as a pleiotropic, multifunctional leukocyte involved 
in the initiation and propagation of inflammatory responses, and, interestingly, as 
modulators between innate and adaptive immunity(9-11). The limited quantity of 
eosinophils—typically comprising only 1-6% of white blood cells(12)— is sufficient in 
light of their ability to secrete various proinflammatory cytokines, chemokines, and lipid 
mediators, in addition to cytotoxic cationic proteins that are capable of inducing direct 
tissue damage and dysfunction(9,10).   
 Unfortunately, certain targets are essentially innocuous, resulting in eosinophil-
derived pathologies directly caused by the increased infiltration of activated eosinophils 
into tissues, such as hypereosinophilic syndrome(13,14), eosinophilic esophagitis(15), 
eosinophilic colitis(16), and allergic asthma (17,18) (Fig. 1). Due to its significant 
prevalence, allergic asthma has been studied in great detail over the past twenty-five 
years(18-24). Characterized by eosinophilic inflammation within the airways(19), tissue 
specimens of allergic asthmatics also exhibit marked infiltration of eosinophils into 
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bronchial mucosa and submucosa(20). Subsequent studies have been able to relate disease 
severity directly to the degree of tissue eosinophilia(18,21-24). As such, eosinophils are the 
source of proinflammatory mediators that cause airway epithelial cell damage and loss, 
airway hyperresponsiveness, mucous hypersecretion and airway remodeling following 
fibrosis and collagen deposition(18,21-24). 
 Although a number of inflammatory mediators posses the chemotactic activity 
for eosinophils and, thus, could potentially be involved with tissue eosinophilia in 
asthma, only interleukin-5 (IL-5) has the ability to regulate the growth, differentiation, 
and activation of eosinophils(10,25).  As such, several lines of evidence indicate the critical 
role of IL-5 in the pathophysiology of allergic inflammation and asthma(26-28). One study 
found elevated IL-5 levels in both serum and bronchoalveolar fluid of atopic asthmatic 
patients(26), with a subsequent study finding increased eosinophil numbers and airway 
hyperresponsiveness in response to IL-5 inhalation(27). Similar increases in eosinophils, 
TH2 cells, and IL-5 were found in bronchial mucosa of biopsies from severe asthmatic 
patients(28).  
 Using the mouse asthma model, two individual laboratories further demonstrated 
the importance of IL-5 in eosinophil accumulation within the asthmatic airway.(29,30) In 
an earlier study, researchers found that CD4+, rather than CD8+, T-cells mediate 
eosinophil recruitment in allergic airways, and that CD4+ derived IL-5 is directly 
responsible for such eosinophil recruitment.(29) A second study provided further 
confirmation, since eosinophilia, lung damage and airway hyperreactivity were entirely 
eliminated in IL-5-deficient mice, with the reconstitution of IL-5 restoring allergen-
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induced eosinophilia and airway dysfunction.(30) Additionally, administration of a 
neutralizing IL-5 antibody, prior to antigen inhalation, suppressed airway hyperactivity 
in the guinea pig(31) and monkey(32) asthma models.  
 Given the important role of eosinophils in disease pathogenesis, understanding 
mechanisms that limit the degree of eosinophilic activation are critically important for 
attenuating eosinophil-derived inflammatory signals. Specifically, much is to be 
understood about the intracellular signaling that occurs following IL-5-mediated 
eosinophil activation. Through our increased understanding of the IL-5 receptor biology, 
our long-term goal with this study is to develop in vivo interventional strategies for 
manipulating eosinophil activity.   
 Eosinophil activation is critically dependent on IL-5 and signaling by its 
receptor, IL-5R, comprised of a ligand specific α-chain (IL-5Rα) and a shared signaling 
component (βc). Our previous studies revealed novel insight into the downregulation of 
IL-5R, specifically IL-5-dependent βc ubiquitination that is required for IL-5R 
endocytosis, proteasomal degradation, and optimal signal transduction.(33) Considering 
that IL-5Rα is the subunit that is specific for IL-5, we sought to explore whether the 
function of this receptor chain was regulated by ubiquitination, and if so, to identify the 
molecular determinants regulating this process.   
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FIGURE 1. Eosinophils in disease. The overproduction of IL-5 and eosinophilia are 
involved in the pathogenesis of specific inflammatory disorders affecting various organ 
systems throughout the body.  
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The IL-5, IL-3 and GM-CSF Receptor Complexes 
 Cytokines are secreted by cells of the hematopoietic lineage, and provide either 
regulation of hematopoietic cell differentiation and/or induce changes in immune cell 
function(34,35). IL-5, interleukin-3 (IL-3), and granulocyte-macrophage colony-
stimulating factor (GM-CSF) are members of the short-chain 4-α-helical subset of 
hematopoietic cytokines, further grouped by their shared use of βc within their 
heterodimer receptors(36). The high affinity receptor complexes for each of these 
cytokines are composed of a ligand specific α-chain (approximately 65 kDa) and the 
shared, signaling βc subunit (130 kDa)(36) (Fig. 2). Alone, each α-chain binds its 
respective cytokine with low affinity (KD = 0.2-100 nM), with the recruitment of βc 
converting the binding to high affinity (KD = 100 pM)(37). Due to the physical and 
conformational proximity of the subunits, the resulting heterodimerization initiates 
receptor activation and intracellular signaling for desired physiological effect.  
 The hematopoietin receptor family is structurally characterized by an 
extracellular domain, of approximately 200 amino acids, containing two fibronectin type 
III domains with a conserved membrane proximal WSXWS motif, as well as membrane 
distal pair of cysteine residues(34-36) (Fig. 3). Although the α-chains exhibit these 
conserved features, βc has a longer extracellular portion due to an additional pair of 
fibronectin type III domains. Common to all cytokine receptors, the cytoplasmic domain 
of the three α-chains and βc express the Box 1 and Box 2 motifs, with the highly 
conserved Box 1 motif known to be required for JAK kinase binding (38-40). It is believed 
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that the significantly longer cytoplasmic domain in βc contains necessary sequences 
required for the initiation and regulation of signal transduction(36).  
 Interestingly, GM-CSFα and IL-5Rα exist as soluble external domains generated 
from the alternative splicing of the GM-CSFα and IL-5Rα genes(41,42). These soluble 
external domains are able to compete with the transmembrane GM-CSFα and IL-5Rα for 
binding with GM-CSF and IL-5, respectively. However, these receptor soluble isoforms 
are unable to participate in cytokine signaling, lacking the necessary cytoplasmic 
domains, with their exact physiological purpose in immunity yet to be determined.  
 Furthermore, the crystal structure of the extracellular GM-CSF ligand-receptor 
complex has been solved(43). Investigators found that the ligand-bound GM-CSFR 
complex exists as a hexamer (2 alpha chains, 2 βc, and 2 GM-CSF molecules) capable of 
supporting differentiation signals. Surprisingly, they also found that each hexamer could 
form a larger dodecamer complex (12-subunit) with another GM-CSFR hexamer for 
additional signaling that supports proliferation in addition to differentiation signaling. 
Interestingly, mutations of βc, at the site of dodecamer interface, reduced signaling and 
function following GM-CSF stimulation, but surprisingly also from IL-3 stimulation (43). 
Together these data suggest that the dodecamer formation may in fact be a conserved 
mechanism utilized by the GM-CSF/IL-3/IL-5 family for optimal receptor activation and 
signal transduction.  
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FIGURE 2. Family of hematopoietic cytokine receptors that share beta-common 
chain (βc) receptor. The hematopoietic receptor family is composed of a heterodimer, 
consisting of a ligand-specific α-chain and beta-common chain (βc), shared among all 
three α-chain receptors. Compared to the short cytoplasmic domain of the α-chains, βc 
significantly longer cytoplasmic region aids in its function of cell signaling.   
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FIGURE 3. Structural components of βc and ligand-specific α-chains. (E) 
Extracellular domains of each α-chain composed of membrane proximal WSXWS motif 
(yellow), characteristic to Type I cytokine receptors, and a homology module of two 
fibronectin type III domains with paired cysteine residues (solid black lines). Similar 
extracellular domain is found in βc, although longer due to the presence of an additional 
pair of cysteine residues and homology modules. (T) Transmembrane region of receptors 
(blue). (C) Cytoplasmic domains of α-chain and βc all contain Box 1 and Box 2 motifs 
(white boxes), although βc cytoplasmic region is notably longer for downstream 
signaling purposes.* 
 
 
 
 
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!*!Reprinted with permission from “Biology of common β receptor-signaling cytokines: 
IL-3, IL-5, and GM-CSF” by Moczygemba MM and Huston DP, 2003. Journal of 
Allergy and Clinical Immunology, 112, 653-665, Copyright (2003) by Elsevier. 
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Intracellular Signaling Cascades  
 Similar to external stimuli such as growth factors and cytokines, IL-5 exerts its 
biological effects after binding its receptor on the surface of target cells(44-48). The 
initiation of signal transduction, following recruitment of βc to the ligand-bound IL-5Rα, 
ultimately results in the reprogramming of gene expression to alter behavior of target 
cells. Currently, four primary signaling pathways have been described for IL-5: Janus 
kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, the 
mitogen-activated protein kinase (MAPK) pathways, the c-JNK/p38 pathway, and the 
phosphatidylinositol 3-kinase (PI3-K) pathway(44-48).  
 
The JAK/STAT Pathway 
The JAK/STAT pathway is utilized by all cytokines to transmit extracellular 
signals, through transmembrane receptors, to the promoters of target genes within the 
nucleus of activated cells(49,50). Thus, the JAK/STAT pathway is remarkable in achieving 
transcriptional gene regulation without the use of secondary messengers. Additionally, 
the evolutionary conservation from slime molds to humans of the JAK/STAT pathway 
further confirms its biological significance(49).  
In the absence of IL-5, JAK1 and JAK2 are constitutively associated with βc and 
IL-5Rα, respectively(51). Specifically, a canonical Proline-X-Proline motif in the Box 1 
region of Type I and II cytokine receptors is required for both JAK kinase binding and 
activation(38-40). Following IL-5 binding to IL-5Rα, βc is recruited close enough to IL-
5Rα that the two JAK proteins are able to transphosphorylate one another. Previous 
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studies have shown that the kinase-negative form of JAK2 resulted in both JAK1 and 
JAK2 inhibition, whereas the kinase-negative form of JAK1 only inhibited JAK1 
activity, highlighting the importance of JAK2 as the main signaling kinase (51). 
Tyrosine-phosphorylated JAK1 and JAK2 are then activated to phosphorylate 
tyrosine residues on βc and IL-5Rα, respectively. Specifically, JAK activation results in 
the phosphorylation of six crucial tyrosine (Y) residues on βc: Y577, Y612, Y695, Y750, 
Y806, and Y866(44-48). Of these six residues, Y612, Y695, and Y750 serve as a docking 
site for the phosphotyrosine-binding SH2 domains of STAT1 and STAT5(49,50). Once 
bound to phosphorylated tyrosine residues on the receptor, STAT proteins themselves 
are activated via JAK-mediated tyrosine phosphorylation. This phosphotyrosine event 
allows for the dimerization of STAT proteins through interaction of their SH2 domains 
with one another. Phosphorylated STATs then enter the nucleus via the Ran nuclear 
import pathway to activate transcription of various proteins involved with eosinophil 
growth, survival and activation(49,50). 
 
The MAPK Pathways 
 The MAPK pathways include the extracellular signal-regulated kinase (ERK), c-
Jun amino-terminal kinase (JNK) and p38 signaling cascades, responsible for a variety 
of cell processes such as growth, proliferation and survival(44-48). The phosphorylation of 
Y577 on βc by JAK2 results in the recruitment of the cellular substrate Shc, which itself 
becomes tyrosine phosphorylated. Tyrosine phosphorylation of Shc allows it to interact 
with the SH2 domain of growth factor receptor-bound adaptor protein Grb2. The 
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Shc/Grb2 complex associates with the nucleotide exchange factor for Ras, resulting in a 
successive activation of Ras, Raf-1, MEK and ERK. The downstream targets of the ERK 
pathway are transcription factors ATF2 ad TCF, which activate c-Fos and c-Jun in order 
to induce cellular proliferation(52).   
 
The PI3-K Pathway 
 Upon cytokine stimulation, PI3-K is activated in a tyrosine phosphorylation-
dependent manner, with previous studies having found a direct link between IL-3-
stimulated βc serine phosphorylation, PI3-K activation, and hematopoietic cell 
survival(53-55). Specifically, IL-3 stimulation induces the activation of protein kinase A, 
which phosphorylates Serine585 on βc(54). The phosphorylated-serine residue then serves 
as a recruitment site for the adaptor protein 14-3-3, which appears to recruit the 
regulatory subunit (p85) and catalytic subunit (p110) of PI3-K to the receptor complex. 
Following PI3-K activation, the secondary messenger phosphatidylinositol 3,4,5-
triphosphate (PIP3) is generated(56,57), resulting in the recruitment and binding of the 
serine-threonine kinase Ak2/PKB(54). Ak2/AKB phosphorylation of BAD results in the 
direct inhibition of apoptosis(55), suggesting that βc Serine585 is critical for hematopoietic 
cell survival.  
 
Signal Termination 
 To ensure that the execution of specific signals are of adequate strength and 
delivered for appropriate time, organisms have developed regulatory mechanisms to 
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safeguard the transient nature of signaling pathways(36). Currently, several forms of 
regulatory mechanisms have been discovered for IL-3, IL-5, and GM-CSF receptors(58-
61).  
 One known mechanism involves the activation of cytosolic tyrosine 
phosphatases, responsible for regulating the ligand-induced phosphorylation of 
substrates(58). Specifically, researchers found that the tyrosine phosphatase Src homology 
protein tyrosine phosphatase 1 (SHP1) was involved in βc downregulation, due to the 
suppression of cell growth following IL-3 stimulation in SHP1 overexpressed cells(58).  
 Another mechanism for terminating IL-3, IL-5 and GM-CSF signals is the 
induction of the suppressors of cytokine signaling (SOCS) family of small SH2-
containing proteins(59). SOCS proteins are known to negatively regulate signaling by 
blocking the access of STATs to receptor binding site, direct inactivation of JAK 
kinases, and ubiquitination of signaling proteins for proteasomal degradation(59).  
 A third mechanism that antagonizes IL-3, IL-5, and GM-CSF signaling is 
receptor endocytosis and degradation(60,61). Previous research within the Huston and 
Moczygemba lab found that βc is first tyrosine phosphorylated and then ubiquitinated in 
response to IL-5 binding, with such events triggering receptor internalization via 
endocytosis(60) (Fig. 4). Within the late endosome, the signaling portion of βc undergoes 
proteasomal cleavage, resulting in the truncated βc product known as βc 
intracytoplasmic proteolysis (βIP). The remaining IL-5R complex, comprised of βIP and 
IL-5Rα, are then degraded in the lysosome for signal termination. Interestingly, use of a 
proteasomal inhibitor prolonged the activation of βc, JAK2, and STAT5, highlighting 
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the ubiquitin proteasomal pathway as rapid technique in terminating βc signal 
transduction(60). Since similar results were found following IL-3 and GM-CSF 
stimulation, it is possible that the ubiquitin/proteasomal-degradation pathway is a 
conserved regulatory mechanism used by βc, and possibly by the α-chains.  
 
Ubiquitin, Endocytosis, and Signaling  
 The ubiquitin/proteasome (Ub/Pr) degradation pathway is the principle 
mechanism for intracellular protein degradation in the mammalian cytosol and 
nucleus(62-68).  This proteolytic system is tightly controlled, and alterations in this 
pathway are associated with the pathogenesis of various diseases such as Parkinson’s, 
Alzheimer’s, Huntington’s disease, and multiple myeloma(69).   
 The classical function of the 8kDa protein, ubiquitin, is associated with 
housekeeping functions, as well as regulation of protein turnover, and antigenic peptide 
generation(62-64).  However, over the past fifteen years, ubiquitin has garnered the label of 
‘master regulator’ of the cell, wherein protein modification by this molecule has the 
potential to regulate cellular processes as diverse as endocytosis, trafficking, cell cycle 
progression, signal transduction, inflammation, apoptosis, neural and muscular 
degeneration, and transcription(62-64). 
 Ubiquitin can be covalently linked to itself and to other substrate proteins either 
as a single molecule (monoubiquitination, monoUb) or a chain of ubiquitin molecules 
(polyubiquitination, polyUb)(62). In general, polyUb chains, formed through Lysine48 and 
Glycine76 linkages, are attached to substrates destined for proteasome degradation.  In 
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contrast, polyUb chains formed through Lysine29 or Lysine63 have other non-proteolytic 
functions in cells, such as transcriptional regulation and membrane trafficking(65-68).  
Other types of protein ubiquitination, such as monoUb and multi-monoUb, are involved 
in at least three distinct cellular functions: histone regulation, endocytosis, and the 
budding of retroviruses from the plasma membrane(65-68).   
 The pioneering work of P.P. Di Fiore and colleagues has firmly established that 
ubiquitin regulates protein transport between membrane compartments, by serving as a 
sorting signal on protein cargo and through controlling the activity of trafficking 
machinery(66,67).  MonoUb and Lysine63-linked poly-Ub chains appended to integral 
membrane proteins serve as regulated signals for internalization into the endocytic 
pathway(66,67).  Interestingly, our laboratory has detected immunoreactivity of βc with 
polyclonal antibodies against Lysine63-linked poly-Ub chains, indicating that βc is 
modified by this type of Ub chain, possibly for endocytic trafficking (unpublished data). 
! 15!
 
FIGURE 4. Current model of βc downregulation following IL-5 stimulation. Step 1: 
binding of IL-5 to the IL-5R complex results in JAK2/1 and Lyn kinase activation, and 
subsequent βc ubiquitination (Ub) and tyrosine phosphorylation (P) by the JAK kinases. 
Step 2: JAK kinase activation triggers the entry of full-length IL-5R complex into the 
lipid raft endocytic pathway. Step 3: Within the endocytic pathway, proteasomes cleave 
the signaling portion of βc cytoplasmic domain for signal termination, generating 
truncated βIP protein as a result. Step 4: Following proteasomal cleavage of βc’s 
signaling cytoplasmic domain, βIP and IL-5Rα are degraded in the lysosome.* 
  
 
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* Reprinted with permission from “JAK kinases control IL-5 receptor ubiquitination, 
degradation, and internalization” by Moczygemba MM, Huston DP, and Lei JT, 2007. 
Journal of Leukocyte Biology, 81, 1137-1148, Copyright (2007) by The Society for 
Leukocyte Biology. !
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Specific Aims   
 Although the endocytic pathway has been historically viewed as a mechanism of 
receptor downregulation, recent studies have shown that signal transduction continues 
throughout the endocytic route(70-73). As such, several studies have explored the 
connection between receptor tyrosine phosphorylation and endocytosis in the 
transforming growth factor-β receptor, acetylcholine receptor, protease-activated 
receptor, and tropomyosin receptor kinase A receptors(74-77). Our previous studies with 
the IL-5R have shown that inhibition of endocytosis prevents association of pSTAT5 
and pMAPK with the IL-5R complex. Thus, entry of IL-5R into the endocytic pathway 
is another mechanism that permits the interaction of βc with its signaling molecules(78). 
 Following the discovery that ubiquitin regulates protein transport, and in certain 
situations directly serve as signals into the endocytic pathway, it was first important to 
further understand the role of ubiquitin in IL-5R, specifically within the signaling 
component, βc. Initial studies found that IL-5R signaling was partially terminated due to 
ubiquitin/proteasomal degradation of βc’s signaling component, followed by the 
lysosomal degradation of the truncated receptor complex(60). More recent studies in the 
Moczygemba laboratory have shown that a cluster of three lysine residues, proximal to 
the plasma membrane, were required for JAK1/2 binding to βc and receptor 
ubiquitination, and that this binding is required for receptor ubiquitination, endocytosis, 
and signaling(33). 
 Since IL-5Rα is the IL-5-specific binding receptor chain for the complete IL-5R, 
we sought to investigate the interplay of IL-5Rα ubiquitination and IL-5R endocytosis 
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and signaling.  In this study, we will apply similar molecular, cellular, and biochemical 
techniques to investigate the potential role of ubiquitination in IL-5Rα function.  The 
major goal of this study is to identify specific ubiquitination sites in the cytoplasmic 
domain of IL-5Rα and define the functional importance of these novel ubiquitination 
events.  Due to the specific and unique expression of IL-5Rα in eosinophils, results from 
this study have the potential to identify new directions in future therapeutics for 
eosinophilic disorders.  We propose the following specific aims to achieve these goals:  
1) Test the hypothesis that IL-5Rα is ubiquitinated and identify key receptor 
ubiquitination sites  
2) Determine the functional significance of IL-5Rα ubiquitination  
3) Determine the role of JAK kinases in IL-5Rα ubiquitination 
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EXPERIMENTAL PROCEDURES  
 
Cell Culture, Materials, and Inhibitors 
 Human embryonic kidney line, HEK293 (purchased from ATTCC) was kept in 
DMEM media supplemented with 10% FBS and 10 µg/ml gentamicin. The human 
erythroleukemic cell line, TF-1, endogenously expresses the IL-5 receptors, and was 
cloned by limited dilution in media with 5 ng/ml IL-5. The TF1-F11 clone was selected 
due to its strong proliferative response to IL-5, 1L-3 and GM-CSF. This clone was 
maintained in RPMI 1640 with 10% FBS, 10 mM β-mercaptoethanol, 10 µg/ml 
gentamicin, and 5 ng/ml human IL-5. Recombinant human IL-5 was expressed by a 
baculovirus and purified via affinity chromatography(79).  
 Cyclohexamide was purchased from Calbiochem and used at a 10 µg/ml 
concentration. Antibodies used for immunoflourescence microscopy and flow Cytometry 
were purchased from the following companies: anti-βc (R&D Systems), anti-βc (clone 
3D7, BD Biosciences), anti-IL-5Rα (R&D Systems), anti-IL-5Rα (N-20, Santa Cruz 
Biotechnology), anti-actin (Santa Cruz Biotechnology), anti-JAK1 (Cell Signaling), anti-
JAK2 (Cell Signaling), anti-STAT5 (Santa Cruz Biotechnology), anti-Ubiquitin (Santa 
Cruz Biotechnology), anti-phospho-STAT5 (Millipore), anti-phospho-JAK2 (Cell 
Signaling), PE-conjugated rat anti-mouse IgG1 (BD Biosciences), and FITC-conjugated 
donkey anti-goat IgG1 (Santa Cruz Biotechnology).  
 
 
! 19!
Construction of IL-5Rα Mutants and Generation of Stable Cell Lines 
 WT IL-5Rα (GenBank™Accession #NM000564)(80) cloned in a pLentivector as 
a template for site directed mutagenesis of IL-5Rα cytoplasmic lysines 1-4 to arginine 
using the multisite site-directed mutagenesis kit (Stratagene) in stepwise manner with 
specific primers listed in Table 1. All lysine to arginine mutations were sequenced to 
confirm the amino acid mutation. The mutated cDNA was then cloned into a Virapower 
pLentivector (Invitrogen), and constructs were fully sequenced. Lentiviral particles 
containing the mutated receptor were made per manufacturer’s instructions, purified 
using Amicon Ultrafiltration tubes (Millipore), and then titered in HeLa cells for stable 
transduction. Initially we established a parental cell line of HEK293 expressing WT βc 
only, to which lentiviral particles were added for transduction of the mutant IL-5Rα. 
Surviving transduced cells were selected in presence of 6 µg/ml blasticidin, and sorted 
by flow cytometry for confirmation of dual receptor expression.  
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Cyclohexamide Pulse Chase Assay 
 WT and mutant IL-5Rα were pretreated with 10 µg/ml Cyclohexamide for one 
hour. Cells were then stimulated with 10 ng/ml IL-5 and then harvested after 10 minutes, 
20 minutes and 30 minutes of stimulation. Afterwards, cells were lysed using 50 µL of 
RIPA buffer (1% Nonidet P-40, 1% Triton, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium 
phosphate at pH 7.2, 0.2 mM EDTA, 5 mM N-ethylmalemide, 1 mM sodium vanadate, 1 
mM PMSF, 1 µg/ml leupeptin, 1 µg/ml pepstatin) for 20 minutes on ice. 25 µg of lysate 
was resolved by lauryl deodecyl sulfate-PAGE, followed by immunoblot analysis using 
anti-βc (R&D Systems), anti-IL-5Rα (R&D Systems), and anti-actin (Santa Cruz 
Biotechnology). Degradation curves were obtained by measuring the band densities 
using AlphaView software (Alpha Innotech), normalizing βc and IL-5Rα densities using 
actin band densities. The Cyclohexamide treated, 0-hour cells were designated as 100% 
with subsequent time points percent densities calculated with this postulation. Curves 
were drawn with % βc or IL-5Rα desities (y-axis) relative to time following IL-5 
stimulation (x axis).  
 
Flow Cytometry 
 Expression of IL-5Rα and βc was measured by incubating WT IL-5Rα, IL-5Rα 
K2R, IL-5Rα K2,3R, IL-5Rα K3,4R, IL-5Rα K2-4R, and IL-5Rα K1-4R HEK293 cell 
lines (approximately 250,000 cells per tube) in PBS + 2% FBS with anti-IL-5Rα (R&D 
Systems) and anti-βc (BD Biosciences) for 20 minutes on ice. Afterwards, cells were 
washed with FITC-conjugated anti-goat IgG and PE-conjugated anti-mouse IgG1 
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flourophore linked antibodies, respectively. Immediately the labeled proteins were 
analyzed using an Accuri C6 (Accuri Cytometers) flow cytometer. The data was then 
analyzed using a CFlow Plus (Accuri Cytometers) software and then graphed using 
Excel.  
IL-5Rα Endocytosis Assay 
Following IL-5 stimulation, we developed an assay that measures the loss of cell-
surface IL-5Rα in WT and IL-5Rα K2R mutant cell line. First, anti- IL-5Rα (N-20, 
Santa Cruz Biotechnology)—which doesn’t prevent IL-5 binding to the receptor—was 
added to the pre-chilled cell lines for thirty minutes on ice. Then the cells were washed 
three times with ice-cold media to remove any unbound antibodies. 10 ng/ml IL-5 was 
then added to cells, with aliquots of the cells being transferred to 37°C for 5, 10 and 15 
minutes. After the respective time at 37°C, receptor internalization was halted by the 
addition of cold PBS. The remaining IL-5Rα receptors on the cell surface were analyzed 
by incubating the anti-IL-5Rα bound receptors with FITC-conjugated anti-goat IgG and 
then measured by flow cytometry. The MFI at 0 minutes (no IL-5 stimulation) 
represented 100% IL-5Rα expression and the loss of immunoreactivity (MFI) was 
determined for the subsequent time points.  
Immunopercipitation and Immunoblot Assays (IP/IB) 
All IP/IB assays were performed as previously described with the following 
antibodies: IL-5Rα was immunopercipated with anti-IL-5Rα polyclonal goat; IBs were 
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done with anti-IL-5Rα monoclonal mouse; anti-ubiquitin mAb (P4D1) (Santa Cruz 
Biotechnology); anti-actin rabbit pAb (Sigma); anti-phosphotyrosine (mAb clone 4G10) 
and anti-pSTAT5 (Upstate Biotechnology); Anti-STAT5 (BD Biosciences). We 
visualized proteins after incubating with enhanced chemiluminescence with reagents 
(GE Healthcare) and images were captured with FuorChem 8000 Imaging System 
(Alpha Innotech).   
Cell Surface Biotinylation Assay 
HEK293 cells were grown to 80% confluency in 100 mm plates and cell surface 
proteins were labeled with a non-permeable sulfo-NHS-SS-biotin reagent (Thermo 
Fisher). First cells were washed with 10 mL cold PBS pH 8.0 before addition of 10 mL 
PBS pH 8.0 containing 0.5 mg biotin reagent. Cell surface proteins were labeled with 
biotin following 30 minutes of rocking at 4°C. Unbound biotin was removed by 
centrifuging the cells five times with 50 mL PBS glycine, before resuspending the pellet 
in 10 mL chilled serum containing DMEM media. Cells were split into two tubes, one 
remaining on ice to inhibit endocytosis and the other being stimulated with 10 ng/ml IL-
5 for 30 minutes at 37°C. After washing with PBS, cell pellets were re-suspended in 500 
µL of PBS with the addition of 0.5 µg of R&D α-IL-5Rα for two hours on ice to bind all 
IL-5Rα receptors on the cell surface. Cells were then washed three times with PBS to 
remove any unbound antibody and then lysed with 300 µL of RIPA lysis buffer. Cell 
surface immune complexes were then precipitated using 15 µL of Protein G, separated 
LDS-PAGE, and transferred to Immobilon-P PVDF membranes. Cell surface biotin 
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labeled proteins was then detected by incubating the membranes with Neutravidin-HRP 
reagent (Thermo Fisher).  
 
JAK1/2 Knockdown 
 Cell surface IL-5Rα in wild-type cells were analyzed in the context of a JAK1 
and JAK2 knockdown. First cells were split into three 100 mm plates: mock, negative 
control, and JAK1/JAK2 knockdown. After twenty-four hours of incubation, mock cells 
received Opti-MEM and lipofectamine 2000 (Invitrogen). In addition, knockdown cells 
were transfected with SMART pool JAK2 (75 nM) and JAK1 siRNAs (50 nM) whereas 
negative control cells were transfected with a non-target negative control siRNA. Forty-
eight hours post transfection, cells were washed with 10 mL cold PBS pH 8.0, and then 
lysed with 300 µL of RIPA lysis buffer. In certain experiments, we performed the cell 
surface biotinylation in the context of JAK1/2 knockdown. Forty-eight hours post 
transfection, cells were washed with 10 mL cold PBS pH 8.0 and cell surface proteins 
were biotinylated with the addition of 0.5 mg of biotin to 10 mL cold PBS pH 8.0 
following the previous protocol.   
 
JAK2 Overexpression 
 JAK2 was overexpressed in certain cell lines to see the physiological effect of 
overexpression on IL-5Rα ubiquitination. Two 100 mm plates were plated per cell line, 
control pcDNA3 and experimental JAK2 overexpression. Control plates were 
transfected with gene jammer and 3 µg of empty pcDNA3 with Opti-MEM, whereas 
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experimental cells were transfected with 3 µg of plasmid JAK2 in pcDNA3 vector 
(generous gift from Dr. Yu-Lee).  Twenty-four hours post transfection cells were washed 
with cold PBS before resuspending the cell pellet with 300 µL of RIPA lysis buffer. 
Proteins were separated on an LDS-PAGE before being transferred to an Immobilon-P 
PVDF membrane for analysis. ! !!
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RESULTS 
IL-5Rα Ubiquitination in TF1 and HEK293 Cells 
Previous studies in the Moczygemba lab demonstrated that βc is ubiquitinated in 
response to IL-5 stimulation(33). Since the IL-5R complex is a heterodimer of βc and IL-
5Rα, we sought to investigate whether IL-5Rα was also ubiquitinated in the human 
erythroleukemic cell line, TF1, due to its endogenous expression of the receptor 
complex. To examine the ubiquitination status of IL-5Rα, whole cell lysates of TF1 cells 
were immunopercipated (IP) with anti-IL-5Rα antibodies and immunoblotted (IB) with 
anti-ubiquitin antibodies, in the absence (-) or presence (+) of IL-5 (Fig. 5A, top panel). 
IP/IB analysis revealed two highly ubiquitinated smears of differing molecular weights, 
which we will refer to as upper and lower smears. Interestingly, the upper smear 
migrated between 97-191 kDa, while the lower smear migrated between 60-75 kDa.  
Based on the sizes of the smears and the known molecular weights of βc and IL-5Rα, we 
hypothesized that the upper smear contained ubiquitinated forms of βc co-precipitating 
with the anti-IL-5Rα immune complexes, and the lower smear contained ubiquitinated 
forms of IL-5Rα.  
Indeed, IB with anti-βc antibodies confirmed its presence in the IL-5Rα immune 
complexes as a single band in the 97 kDa range rather than a smear, indicating that our 
βc IB antibodies recognize the non-ubiquitinated form of βc (Fig. 5A, middle panel).  
Similarly, IB with anti-IL-5Rα antibodies confirmed our prediction that the lower smear 
corresponded to the location of ubiquitinated forms of IL-5Rα (Fig. 5A, bottom panel). 
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Interestingly, TF1 cells had increased levels of ubiquitination in both upper and lower 
smears following thirty minutes of IL-5 stimulation (Fig. 5A, top panel, lanes 1 vs 2). 
This result of increased ubiquitination in IL-5Rα following IL-5 stimulation is consistent 
with previous studies of βc ubiquitination in TF1 cells(33). 
 After confirming IL-5Rα ubiquitination under endogenous conditions, we sought 
to investigate the ubiquitination status of our model cell system, the human embryonic 
kidney cell line, HEK293, stably transduced with the IL-5R complex. Although HEK293 
do not endogenously express the receptor complex, previous studies using HEK293 cells 
has shown that the IL-5R complex proceeds with normal signaling patterns and 
lysosome trafficking following IL-5 stimulation(78,80). Therefore, the use of HEK293 as 
our study cell model system will allow for phenotypic analysis of IL-5Rα mutants, 
relative to WT IL-5Rα, in order to further understand the role of ubiquitination in this 
receptor.   
 Similar to TF1 cells, IP/IB analysis of IL-5Rα with anti-ubiquitin antibodies in 
HEK293 cells— stably transduced with the WT IL-5R complex— showed the presence 
of two highly ubiquitinated smears (Fig. 5B, top panel). After the membranes were 
stripped and blotted with anti-βc antibodies (Fig. 5B, middle panel) and anti-IL-5Rα 
antibodies (Fig. 5B, bottom panel), the upper and lower smears were identified as 
ubiquitinated forms of βc co-precipitating with anti-IL-5Rα immune complexes and 
ubiquitinated forms of IL-5Rα, respectively. Although TF1 cells appeared to exhibit 
increased ubiquitination following IL-5 stimulation (Fig. 5A, top panel, lanes 1 vs. 2), 
unstimulated and stimulated HEK293 cell lines had comparable levels of ubiquitination 
! 28!
(Fig. 5B, top panel, lanes 1 vs. 2). This is likely caused by the overexpression of IL-5R 
subunits in HEK293 cells, which— as we have seen with βc— may result in receptor 
activation in the absence of ligand(78). 
 Interestingly, IP/IB analysis with anti-IL-5Rα antibodies shows the presence of 
two distinct bands in both unstimulated and stimulated HEK293 cells (Fig. 5B, bottom 
panel). Previous findings in that Moczygemba lab found that the upper, higher molecular 
weight band is glycosylated IL-5Rα, whereas the lower band is most likely an immature, 
unglycosylated form of IL-5Rα. Following treatment a glycosylation inhibitor, Peptide-
N-Glycosidase F (PNGaseF), the ‘smeary’ upper band becomes a tight band that shifts to 
a faster migrating band, co-migrating with the lower band(60). Thus, it is likely possible 
that the higher molecular weight band in our HEK293 cells is most likely glycosylated 
IL-5Rα, whereas the lower molecular weight band is most likely an immature 
unglycosylated form of IL-5Rα. 
 In conclusion, the presence of ubiquitination in TF1 cells confirms that IL-5Rα is 
in fact ubiquitinated, much like βc, in cells that endogenously express the receptor 
complex. Additionally, HEK293 cell lines, transduced with WT IL-5R, show 
comparable levels of ubiquitination and receptor complex expression, allowing us to use 
this cell line as the model cell system. Consequently, having confirmed IL-5Rα 
ubiquitinated, we first sought to determine potential ubiquitination sites through 
sequence analysis of the receptor, in comparison to βc. 
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FIGURE 5. Ubiquitination of WT IL-5Rα in TF1 and HEK293 cell lines. A. TF1 
cells endogenously expressing IL-5R complex were left unstimulated (0 min) or 
stimulated with 10 ng/ml of IL-5 for 30 minutes. Cell lysates were prepared using RIPA 
buffer, IP with anti-IL-5Rα mAbs, and analyzed by IB with indicated antibodies (n = 3). 
B. Same as in A, using HEK293 cells stably transduced with WT IL-5R complex (n = 5).  
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Construction of IL-5Rα K-to-R Mutants 
Established as sole ubiquitination sites, sequence analysis of the cytoplasmic 
signaling portion of βc indicated the presence of sixteen lysine residues. Through the 
construction of several mutant βc receptors with different combinations of lysine-to-
arginine (K-to-R) mutations, previous research in the Moczygemba lab identified a 
cluster of three lysine residues, adjacent or within the Box 1 motif, whose presence were 
required for not only JAK1/2 binding to βc, but also subsequent βc ubiquitination(33). 
Having now also confirmed IL-5Rα ubiquitination, we first sought to determine if there 
are any sequence similarities in the distribution of lysine residues between βc and IL-
5Rα. Sequence analysis of the first 22 amino acids in the IL-5Rα cytoplasmic domain—
proximal to the cell membrane— indicated a similar K-rich region in the vicinity of the 
Box 1 motif with comparable spatial distribution to βc. 
Four lysine residues were located within or adjacent to the Box 1 motif (Fig. 6A), 
specifically Lys363, Lys370, Lys379, and Lys383.  To determine whether the presence of 
these K residues were also involved in IL-5Rα ubiquitination, site-directed mutagenesis 
was performed to substitute each lysine residue with another positively charged amino 
acid, arginine (R), using IL-5Rα cDNA cloned in a lentiviral vector (Fig. 6B).  Since 
both lysine and arginine are positively-charged residues, we predicted that protein 
folding of IL-5Rα would not be significantly disrupted following the K-to-R mutation, 
as observed with similar experiments with βc(33). At the same time, lysine residues are 
canonical sites of ubiquitination, whereas arginine residues are not. Six IL-5Rα mutant 
constructs were generated, each expressing various combinations of K-to-R mutations to 
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devise single (K1R; K2R), double (K2,3R; K3,4R), triple (K2-4R) and quadruple (K1-
4R) mutant IL-5Rα cell lines (Fig. 6B).  Lentiviral particles expressing each mutant IL-
5Rα receptor were stably-transduced into a HEK293 cell line expressing only WT βc 
(Fig. 7), and double receptor expression of sorted cells was evaluated by flow cytometry 
analysis of anti-IL-5Rα-FITC (x-axis) and anti-βc-PE (y-axis) labeled cells (Fig. 8).  
Relative to WT expression of both receptor chains (90.8%), specific mutant cell 
lines had comparable percentages of double-positive cells (Fig. 8)—K1R (97.7%), K2R 
(94.2%), and K3,4R (93.5%)— allowing us to continue in examining the physiological 
effects of the K-to-R mutations in the mutant cell lines. Although certain mutants 
expressed reduced double-positive cells relative to WT—K2,3R (85.7%), K2-4R 
(75.0%), and K1-4R (86.8%)—this varied expression of double receptors may be caused 
by 1) inefficient transduction 2) short residence time on cell surface 3) ineffective 
trafficking to the cell surface.  
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FIGURE 6. Generation of HEK293 expressing WT and mutant IL-5Rα receptors. A, 
schematic illustration of the four intracellular lysine residues on WT IL-5Rα located 
within or adjacent to the Box 1 motif. B, illustration of the six IL-5Rα mutant constructs, 
with different combinations of lysine (K) residues substituted to arginine residues (R) 
following site-directed mutagenesis. All IL-5Rα constructs (WT and mutants) were 
cloned in pLentivector, and stably transduced into βc expressing HEK293 cells, after 
confirming correct K-to-R mutations with sequence analysis. Dual-receptor expressing 
cell lines were selected in the presence of blasticidin (6 µg/ml) and Geneticin (0.85 
mg/ml), and then further sorted to enrich the presence of dual expressing cells. Box 
indicates location of Box 1 motif; TM, transmembrane domain. 
A.  
B.  
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FIGURE 7. Expression of WT IL-5R heterodimer in HEK293. Flow cytometry 
analysis of sorted, dual receptor-expressing HEK293 cells transduced with WT IL-5Rα 
and βc. Cells were labeled with anti-IL-5Rα-FITC (x-axis) and anti-βc-PE (y-axis) 
antibodies. Upper right corner indicates presence of double-positive cells with dual 
receptor expression, i.e. both IL-5Rα and βc.  
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FIGURE 8. Expression of mutant IL-5R heterodimer in HEK293. Flow cytometry 
analysis of sorted, dual receptor-expressing HEK293 cells transduced with mutant IL-
5Rα and WT βc. Cells were labeled with anti-IL-5Rα-FITC (x-axis) and anti-βc-PE (y-
axis) antibodies. Upper right corner indicates percentage of double-positive cells with 
dual receptor expression, i.e. both mutant IL-5Rα and WT βc. 
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Accumulation of IL-5Rα Cell Surface Expression in Certain IL-5Rα K-to-R Mutants 
 First, we wanted to determine if the IL-5Rα K-to-R mutations affected functional 
properties of the receptor, such as cell surface expression under steady state conditions. 
Flow cytometry was used to test our hypothesis that certain mutations would alter the 
cell surface expression of the receptor. After labeling unstimulated cells with anti-IL-
5Rα-FITC antibodies, cell surface expression was measured and we repeated the 
experiment multiple times to obtain mean fluorescence intensity across cell lines. 
Interestingly, our results showed that single and double K-to-R mutations (K1R; K2R; 
K2,3R; K3,4R) resulted in higher cell surface expression relative to WT (Fig. 9; Table 
2). In particular, mutant K3,4R had significantly higher cell surface expression relative 
to WT (p-value: 0.0006). On the other hand, triple and quadruple K-to-R mutations 
exhibited comparable (K2-4R) or decreased (K1-4R) cell surface expression relative to 
WT expression, although these results were not significant (Fig. 9; Table 2).  
 It would be interesting to see if this pattern of cell surface expression was 
maintained following IL-5 stimulation. Thus, the focus of our remaining study will 
evaluate the physiological effects of K-to-R IL-5Rα mutations in cells under steady state 
conditions, and following IL-5 stimulation.  
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FIGURE 9. Cell surface expression of WT and mutant IL-5Rα receptors. Cell 
surface IL-5Rα in unstimulated WT and mutant cells were labeled with anti-IL-5Rα-
FITC antibodies and measured by flow cytometry. Cell surface expression is shown as 
mean fluorescence intensity (MFI) ± standard error (S.E.). (*) Represents statistically 
significant data.  
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Ubiquitination Levels Directly Correlate with Cell Surface Expression of IL-5Rα 
Mutants 
 Previous studies with βc have shown that a cluster of three lysine residues, within 
the vicinity of the Box 1 motif, is crucial for receptor ubiquitination due to the complete 
loss of IL-5-dependent βc ubiquitination following K-to-R mutations of these three 
residues(33). Based on these results, we hypothesized a similar inverse relationship 
between IL-5Rα ubiquitination and cell surface expression, i.e. mutants with higher cell 
surface expression would exhibit decreased ubiquitination, whereas mutants with lower 
cell surface expression would exhibit increased ubiquitination.  
 We analyzed total levels of proteins associated with IL-5Rα by 
immunoprecipitating (IP) IL-5Rα and subsequently immunoblotting (IB) with antibodies 
against our proteins of interest. Similar to our experiments with TF1 and WT HEK293 
cells, upper and lower smears were readily visible following IB with anti-ubiquitin 
antibodies (Fig. 10, top panel). Stripping the membranes and blotting with anti-IL-5Rα 
(Fig. 10, second panel) and anti-βc (Fig. 10, third panel) antibodies confirmed the 
identity of the upper and lower smears as co-immunoprecipitating ubiquitinated-βc and 
ubiquitinated IL-5Rα, respectively.  
 To our surprise, we found ubiquitination of both smears to be higher in particular 
mutants; specifically the IL-5Rα mutants that had increased cell surface expression in 
previous flow cytometry experiments. In unstimulated cells, single and double mutants 
had higher IL-5Rα ubiquitination relative to WT (Fig. 10, top panel, lane 1 vs. lanes 3, 
5, and 7). Following thirty-minutes of IL-5 stimulation, an increase in ubiquitination is 
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apparent in WT (Fig. 10, top panel, lanes 1 vs. 2), K2R (Fig. 10, top panel, lanes 3 vs. 
4), and K2,3R (Fig. 10, top panel, lanes 5 vs. 6). Interestingly, K3,4R not only had the 
highest degree of ubiquitination in unstimulated cells, but also lacked a clear increase in 
ubiquitination following IL-5 stimulation (Fig. 10, top panel, lanes 7 vs. 8). Since the 
K3,4R mutant also had the highest cell surface expression in steady state conditions, it is 
possible that ubiquitin has a novel role in stabilizing cell surface expression in IL-5Rα. 
 Furthermore, it appears that mutants with decreased cell surface expression seem 
to also have decreased ubiquitination under steady state conditions. Specifically, K2-4R 
(Fig. 10, top panel, lane 9) and K1-4R (Fig. 10, top panel, lane 11) have ubiquitination 
expression significantly less than single and double mutants, with ubiquitination in triple 
and quadruple K-to-R mutants returned to WT levels (Fig. 10, top panel, lane 1).  
 Next, we studied the effects of K-to-R mutations on cell signaling by stripping 
the membrane and blotting with anti-JAK2 antibodies (Fig. 10, bottom panel). There is 
an obvious increase in JAK2 association with IL-5Rα following IL-5 stimulation in WT 
(Fig. 10, bottom panel, lanes 1 vs. 2), K2R (Fig. 10, bottom panel, lanes 3 vs. 4), K2,3R 
(Fig. 10, bottom panel, lanes 5 vs. 6), and K3,4R (Fig. 10, bottom panel, lanes 7 vs. 8). 
Furthermore, there is a direct correlation between the extent of JAK2 association with 
IL-5Rα to the degree of IL-5Rα ubiquitination.  Interestingly, in addition to less JAK2 
association under basal conditions in K2-4R and K1-4R mutants, there also was no 
apparent increase in JAK2 association following IL-5 stimulation (Fig. 10, bottom panel, 
lanes 9 vs. 10; lanes 11 vs. 12). These results are most likely caused by the complete, or 
nearly complete, loss of lysine residues in the Box 1 motif. Although the canonical P-X-
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P residues within Box 1 were still intact within K2-4R and K1-4R, the loss of three or all 
four lysine residues within this region may have prevented optimal JAK2 association 
with the receptor, as was found with βc(33). 
 In sum, these results formulate the basis of a unique model for IL-5Rα, whereby 
ubiquitin is linked to its cell surface stability. This is in stark contrast to previous 
research with βc, which indicated an inverse relationship between βc-ubiquitination and 
cell surface expression due to the induction of receptor internalization mechanisms 
triggered by βc-ubiquitination(33). Although, JAK2 expression appears to mirror IL-5Rα 
ubiquitination in WCL studies, it will be interesting to see if JAK kinase binding is 
necessary for optimal IL-5Rα ubiquitination, as found with our βc studies.  
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FIGURE 10. Differential degrees of ubiquitination in IL-5Rα K-to-R mutants. 
Stably transduced HEK293 cells expressing WT or mutant IL-5Rα receptors were 
stimulated with 10 ng/ml of IL-5 for thirty minutes. Lysates were IP with anti-IL-5Rα-
mAbs and analyzed by IB with antibodies indicated on right panel. 
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Dysregulated Cell Surface Expression of IL-5Rα Mutants Partially Explained by 
Degradation Rates 
 Due to the similar patterns among sets of mutants, we decided to further compare 
the consistently highest expressing mutant (K3,4R) and lowest expressing mutant (K1-
4R) to WT IL-5Rα for the remainder of the study. We first sought to examine the 
underlying molecular mechanism of increased or decreased cell surface expression in 
K3,4R and K1-4R, respectively, by mirroring experiments performed with the βc mutant 
that also exhibited impaired cell surface expression(33). Three possible explanations 
could account for the impaired cell surface expression seen in IL-5Rα mutants: 1) 
delayed or accelerated protein degradation in K3,4R and K1-4R, respectively 2) 
decreased or increased endocytosis in K3,4R and K1-4R, respectively 3) accelerated or 
delayed recycling of K3,4R and K1-4R, respectively. 
 First, we sought to determine if delayed or accelerated protein degradation was 
responsible for cell surface expression of K3,4R and K1-4R, respectively, as compared 
to WT IL-5Rα. To test this hypothesis, we compared degradation rates among the three 
receptors by pretreating cells with cycloheximide to halt protein synthesis, and then 
“chased” IL-5Rα protein levels at various time points following IL-5 stimulation by 
Western blot (Fig. 11A). IB with anti-IL-5Rα antibodies indicates an obvious delay in 
K3,4R degradation, relative to WT (Fig. 11A, top panel, lanes 2-4 vs. 6-8). On the other 
hand, K1-4R appears to have accelerated degradation rates, relative to WT (Fig. 11A, 
top panel, lanes 2-4 vs. 10-12).   
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 We repeated this experiment several times, and generated degradation curves by 
measuring IL-5Rα band densities from IBs after normalizing to corresponding actin 
band densities (Fig. 11B). K3,4R had a significantly slower degradation relative to WT 
following 30 minutes of IL-5 stimulation (p-value: 0.0083), with 96% of starting K3,4R 
protein levels remaining compared to 77% of starting WT protein level. This trend of 
delayed K3,4R degradation continued at 60 minutes of IL-5 stimulation, with 86% of 
K3,4R protein levels remaining relative to 74% of WT, although differences in 
degradation were not significant.  
 Even though at 30 minutes IL-5 stimulation, K1-4R had delayed degradation 
relative to WT—with 86% of starting protein levels remaining—the mutant appears to 
have had accelerated degradation rates by 60 minutes of IL-5 stimulation, with 68% of 
starting K1-4R protein levels remaining relative to 74% of remaining WT protein. While 
not statistically significant, reduced K1-4R cell surface expression maybe partially 
attributed to faster degradation rates. These data indicates that K3,4R mutant resulted in 
a ~10% slower turnover rate, whereas K1-4R mutant resulted in a ~10% faster turnover 
rate. Yet, these changes in turnover do not entirely explain the strong differences in cell 
surface expression seen in these two mutants, highlighting the possibility of additional 
regulatory mechanisms in effect. 
 During previous studies with βc, a recycling inhibitor, monensin(81,82), was used 
to determine if increased cell surface expression of mutant βc was due to faster recycling 
back to the cell surface. It was hypothesized that if this mechanism was responsible for 
increased cell surface expression, monensin treated βc mutants would result in increased 
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βc-positive intracellular vesicles with a corresponding reduction in cell surface levels. 
Due to negligible effects of monensin on the mutant βc receptor, impaired recycling was 
discounted as a possible mechanism of increased cell surface expression(33). We 
hypothesized that the same would be true for IL-5Rα receptors, deciding to focus next 
on endocytosis as another contributing mechanism of increased or decreased cell surface 
expression of K3,4R and K1-4R, respectively. 
 
 
FIGURE 11. Partial delay in degradation in K3,4R IL-5Rα. A, WT, K3,4R, and K1-
4R IL-5Rα were either left untreated (−)  or treated (+) with 10 µg/ml of cycloheximide 
(CHX) for 1h, followed by harvesting cells at the specified time points. Whole cell 
lysates (50 µg/lane) were analyzed with anti-IL-5Rα, anti-βc, and anti-actin antibodies. 
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FIGURE 11 CONTINUED. Partial delay in degradation in K3,4R IL-5Rα. B, 
Degradation curves were generating by measuring IL-5Rα band densities from IBs and 
normalized against corresponding actin band densities. The IL-5Rα band density at the 
0-h time point (following 1h pretreatment with cycloheximide) was designated as 100% 
and percent densities of later time points were calculated based on this assumption. 
Averages of percent densities were used for WT (n = 5), K3,4R (n = 4), and K1-4R (n = 
2), with corresponding standard deviation. 
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IL-5Rα Mutants Display Impaired Endocytosis 
 
 The second mechanism we interrogated was whether decreased or increased 
endocytosis in K3,4R and K1-4R, respectively, explained the differences in cell surface 
expression. To test this hypothesis, we performed a cell surface biotinylation assay in 
WT, K3,4R, and K1-4R IL-5Rα expressing cells. All cell surface proteins were first 
biotinylated and then precipitated with biotin-specific neutravidin beads, before 
separating proteins on an LDS-PAGE and blotting with antibodies to our proteins of 
interest. Following IB with anti-IL-5Rα antibodies, unstimulated cells appear to confirm 
previous flow cytometry and WCL studies (Fig. 12A). Specifically, at steady-state 
conditions, K3,4R (Fig. 12A, lane 3) appears to have increased IL-5Rα cell surface 
expression relative to WT (Fig. 12A, lane 1), whereas K1-4R (Fig. 12A, lane 5) exhibits 
decreased IL-5Rα cell surface levels. After thirty minutes of IL-5 stimulation, 
differences across the three cell lines are apparent.  
 In order to better determine the amount of IL-5Rα remaining on the cell surface 
following IL-5 stimulation, densitometry was performed to obtain band densities at 
thirty minutes of stimulation, using steady state conditions as an initial reference. 
Densitometry revealed that 44.8% of WT, 84.8% of K3,4R and 61.77% of K1-4R IL-
5Rα remained on the cell surface following thirty minutes of IL-5 stimulation (Fig. 
12B). These data indicate that the increased cell surface expression seen in K3,4R may 
in fact be due to delayed endocytosis, as seen in our previous βc studies(33). Although the 
mechanism behind increased cell surface expression maybe comparable between IL-5Rα 
and βc, it is very interesting to note that our IL-5Rα mutant with increased cell surface 
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expression also had increased ubiquitination, whereas the βc mutant with increased cell 
surface expression was ubiquitin-deficient(33). 
 To gain further insight into the role of ubiquitin just on receptors located on the 
cell surface, we repeated the experiment and blotted with additional antibodies against 
our proteins of interest (Fig. 12C). We hypothesized that IP/IB analysis of only cell 
surface proteins will confirm steady state trends in our previous results with whole cell 
lysates (Fig. 10)—specifically the role of ubiquitination in stabilizing cell surface 
expression of IL-5Rα receptors.  
 Following precipitation with neutravidin beads, we first immunoblotted with 
anti-IL-5Rα antibodies (Fig. 12C, top panel). Although not strongly visible due to 
exposure, a difference among the three cell lines in unstimulated conditions is apparent, 
with K3,4R having increased cell surface expression (Fig. 12C, top panel, lane 3) and 
K1-4R having decreased cell surface expression (Fig. 12C, top panel, lane 5), relative to 
WT (Fig. 12C, top panel, lane 1). Following thirty minutes of IL-5 stimulation, a 
decrease in cell surface IL-5Rα expression is somewhat present, yet not as obvious as 
the previous western blot, again most likely due to exposure.  
 After stripping the membrane and blotting within anti-ubiquitin antibodies, the 
ubiquitination of all cell surface proteins at steady-state conditions is visible (Fig. 12C, 
second panel). Mirroring cell surface IL-5Rα expression, ubiquitination of all cell 
surface proteins appear to be increased in K3,4R (Fig. 12C, second panel, lane 3) and 
decreased in K1-4R (Fig. 12C, second panel, lane 5), relative to WT IL-5Rα (Fig. 12C, 
second panel, lane 1), under steady state conditions. The most startling finding is the 
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obvious, and dramatic, deubiquitination of all cell surface proteins following thirty 
minutes of IL-5 stimulation (Fig. 12C, second panel, lane 2, 4, 6). This deubiquitination 
event is not caused by loss of cell surface receptors, since IL-5Rα expression is still 
present (Fig. 12C, top panel). Although there is a slight reduction in cell surface IL-5Rα 
receptors following IL-5 stimulation, this decrease is not sufficient to explain the 
complete loss of ubiquitination. Based on previous WCL IP/IB studies and this cell 
surface biotinylation experiment, IL-5Rα is indeed ubiquitinated prior to IL-5 
stimulation, and a key first step in IL-5 signaling may likely involve a deubiquitination 
event of all cell surface proteins. 
 Next, we confirmed βc cell surface expression after stripping the membrane and 
blotting with anti-βc antibodies (Fig. 12C, third panel). βc expression appears to 
correlate with IL-5Rα expression, with K3,4R having higher expression and K1-4R 
having lower expression of βc relative to WT, although differences in βc expression is 
not as visibly apparent.  
 Lastly, we sought to confirm βc activation at the cell surface by stripping the 
membrane and blotting with anti-phosphorylated-tyrosine antibodies (Fig. 12C, fourth 
panel). Indeed, IL-5-dependent JAK kinase-activation was also confirmed at the cell 
surface, with increased tyrosine phosphorylation evident only after 30 minute IL-5 
stimulation (Fig. 12C, fourth panel, lanes 2, 4, 6). Although reduced tyrosine 
phosphorylation levels were detected in K1-4R (Fig. 12C, fourth panel, lane 6), this is 
most likely caused by the decreased levels of βc that co-immunoprecipitated with the 
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immune complex (Fig. 12C, third panel, lane 6). Interestingly, the deubiquitination 
event of cell surface proteins appears to occur alongside JAK kinase signaling.  
 Taken together, cell surface biotinylation assay provide results that the 
mechanism of increased cell surface expression in K3,4R and K1-4R may in fact be due 
to impaired endocytosis (Fig. 12A, 12B). Surprisingly, it also appears that not only are 
cell surface proteins ubiquitinated in steady state conditions, a massive IL-5-dependent 
deubiquitination event occurs following IL-5 stimulation (Fig. 12C, second panel).  
 
 
 
 
FIGURE 12. Dramatic de-ubiquitination event following IL-5 stimulation of cell 
surface proteins. A, WT, K3,4R, and K1-4R IL-5Rα expressing HEK293 cell lines were 
cell surface labeled with the nonpermeable sulfo-NHS-SS-biotin reagent. Briefly, 
labeled cells were either left unstimulated or stimulated with 10 ng/ml of IL-5 for thirty 
minutes. Following cell lysis, lysates incubated with neutravidin beads and all 
biotinylated cell-surface analyzed by IP with Neutravidin-HRP antibodies, and blotted 
with anti-IL-5Rα antibodies. 
A.!
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FIGURE 12 CONTINUED. Dramatic de-ubiquitination event following IL-5 
stimulation of cell surface proteins. B, densitometry analysis to quantify the percentage 
of WT and mutant IL-5Rα receptors remaining on the cell surface following IL-5 
stimulation, after using steady state conditions as an initial reference. C, repeated the 
experiment described in A, with the membrane stripped and blotted with additional 
antibodies against proteins of interest.  
B.!
C.!
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JAK1 and JAK2 are Necessary for IL-5Rα Ubiquitination 
 Past research has shown the necessity of the Box 1 motif for JAK kinase binding 
to Type I and II cytokine receptors, due to reduced binding and activation of JAKs 
following mutation of these proline residues(38-40). Previous studies with βc demonstrated 
that the presence of JAK1 and JAK2 were required for optimal βc ubiquitination, and 
subsequent signal transduction(33). Therefore, we decided to investigate whether a similar 
relationship was present for WT IL-5Rα. We used combinatorial RNAi to 
simultaneously silence both JAK1 and JAK2 in HEK293 cells stably expressing WT IL-
5R complex. If JAK kinases were involved in optimizing IL-5Rα ubiquitination, we 
hypothesized that JAK knockdown cells will result in a corresponding reduction in IL-
5Rα ubiquitination.  
 First, we wanted to confirm successful knockdown of the JAK proteins (Fig. 13). 
Relative to scramble control, JAK1 had 77.1% knockdown efficiency at steady state 
conditions (Fig. 13, top panel, lane 3 vs. 5) and 63.9% knockdown efficiency at 30 
minute IL-5 stimulation (Fig. 13, top panel, lane 4 vs. 6). Furthermore, relative to 
scramble control, JAK2 had 79.6% knockdown efficiency at steady state conditions (Fig. 
13, second panel, lane 3 vs. 5) and 65.9% knockdown efficiency at 30 minute IL-5 
stimulation (Fig. 13, second panel, lane 4 vs. 6).  
 After confirming successful knockdown, we proceeded to examine the 
ubiquitination of IL-5Rα by our standard IP/IB analysis in the absence or presence of IL-
5. We repeated the knockdown experiment and lysates were immunoprecipitated with 
anti-IL-5Rα antibodies and then blotted with IL-5Rα to confirm receptor expression 
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(Fig. 14, top panel). Relative to scramble control, IL-5Rα expression was not 
significantly altered in JAK1/2 knockdown cells.  
 Next we stripped the membrane and blotted with anti-ubiquitin antibodies. Our 
data revealed that in the absence of JAKs, IL-5Rα ubiquitination was partially reduced in 
steady state conditions relative to scramble control (Fig. 14, bottom panel, lanes 3 vs. 5). 
This finding is in contrast with previous βc studies, which found a negligible effect of 
basal βc ubiquitination in the absence of JAK1/2(33). Similar to βc results, loss of JAK1/2 
expression resulted in a partial decrease in IL-5Rα ubiquitination relative to scrambled 
siRNA control (Fig. 14, bottom panel, lanes 4 vs. 6). Overall, JAK1 and JAK2 gene 
silencing partially prevented IL-5Rα ubiquitination, although residual ubiquitination of 
the receptor was still present. Thus, other ubiquitination mechanisms must be involved 
in supporting a model whereby JAK kinases are required for optimal, but not entire, IL-
5Rα ubiquitination.  
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FIGURE 13. Successful JAK1 and JAK2 knockdown in HEK293 WT IL-5R cells. 
HEK293 cells expressing WT IL-5Rs were transfected with both JAK1 and JAK2 
siRNAS, or scrambled –C siRNAs for 48h as described under “Experimental 
Procedures.” Whole cell lysates, in the absence or presence of 10ng/ml IL-5, were 
analyzed by IB with both anti-JAK1 and anti-JAK2 antibodies to determine knockdown 
efficiencies of JAK1 and JAK2, respectively. Band densities were normalized using 
corresponding actin band densities. –siRNA was designated as 100% to determine 
percent knockdown of JAK1 and JAK2.  
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FIGURE 14. JAK1 and JAK2 are partially involved in regulating IL-5Rα 
ubiquitination. HEK293 cells expressing WT IL-5Rs were transfected with both JAK1 
and JAK2 siRNAS, or scrambled –C siRNAs for 48h as described under “Experimental 
Procedures.” Whole cell lysates, in the absence or presence of 10ng/ml IL-5, were 
further analyzed by IB with the indicated antibodies to determine the role of JAK1/2 in 
IL-5Rα ubiquitination.   
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JAK-Mediated IL-5Rα Tyrosine Phosphorylation Dependent on Two Key Lysine 
Residues 
 We chose to conclude our studies by examining the potential impairment of K-
to-R mutations on IL-5 induced cell signaling. Our previous studies with βc receptor 
showed reduced JAK binding and signaling if lysine residues within or surrounding the 
Box 1 motif were mutated to arginine(33). Thus, we hypothesized that our IL-5Rα 
mutants would exhibit impaired JAK binding and signaling, specifically the K1-4R 
mutant due to loss of all four lysine residues. To this end, we overexpressed JAK2, using 
pcDNA3 in the presence of GeneJammer, in both WT and K3,4R IL-5Rα cells.  In light 
of our knockdown experiments, we hypothesized that overexpression of JAK2 would 
results in enhanced IL-5Rα tyrosine phosphorylation. We first confirmed JAK2 
overexpression after immunoprecipitating with anti-IL-5Rα antibodies and 
immunoblotted with anti-JAK2 antibodies (Fig. 15, first panel). Although endogenous 
levels are difficult to detect, overexpression cell lines have obvious JAK2 expression at 
steady state conditions (Fig. 15, first panel, lanes 3 and 7) and following thirty minutes 
of IL-5 stimulation (Fig. 15, first panel, lanes 5 and 8).  
 Although tyrosine phosphorylation could not be detected in either WT or K3,4R 
cell lines under endogenous conditions, JAK2 overexpression lanes provided interesting 
results. In JAK2 overexpressing WT cell lines, two major phosphorylated tyrosine bands 
are clearly visible (Fig. 15, third panel, lanes 3 and 4). As expected, the higher 
molecular weight is confirmed to be tyrosine phosphorylated βc after stripping the 
membrane and blotting with anti-βc antibodies (Fig. 15, fourth panel). Surprisingly, the 
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lower molecular weight appears to be tyrosine phosphorylation IL-5Rα, the first 
scientific evidence of the receptor’s tyrosine phosphorylation. In JAK2 overexpressing 
K3,4R cell lines, βc tyrosine phosphorylation was easily detected in cells overexpressing 
JAK2 (Fig. 15, third panel, lanes 7 and 8). However, there is a distinct absence of IL-
5Rα tyrosine phosphorylation even though JAK2 was clearly overexpressed. Thus, this 
reduction in IL-5Rα tyrosine phosphorylation is not due to the inability of JAK2 to 
associate with the receptor, but rather a consequence of K3,4R mutagenesis.  This result 
highlights a specific role of the third and fourth lysine residues in optimizing JAK2 
signaling.  
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FIGURE 15. Lack of tyrosine phosphorylation in K3,4R IL-5Rα. HEK293 cells 
expressing WT or K3,4R IL-5Rα were transfected with a JAK2 overexpression vector 
using GeneJammer or with a control vector (pcDNA3).  Whole cell lysates from 
unstimulated and cells stimulated with 10ng/ml IL-5 were immunoprecipitated with anti-
IL-5Rα mAbs and analyzed by IB with indicated antibodies.  Note the lack of IL-5Rα 
tyrosine phosphorylation in the third panel, bottom bands (lanes 3 & 4 vs. lanes 7 & 8).  
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DISCUSSION AND CONCLUSIONS 
 
 The IL-5 receptor complex is a heterodimer composed of the ligand-specific α-
chain, IL-5Rα, and a signaling component, βc, shared with both IL-3Rα and GM-
CSFRα(34,35). Previous studies have shown that IL-5-binding induces βc ubiquitination, 
which then regulates βc endocytosis and turnover, and this ubiquitination of βc is 
dependent on the presence of three cytoplasmic lysine residues, Lys457, Lys461, and 
Lys467(33). Due to a similar cluster of lysine residues within IL-5Rα, we sought to 
determine if IL-5Rα is regulated by ubiquitination in our HEK293 cell model system and 
if so, to identify the functional significance of such ubiquitination.  
 Based on our current findings, we propose the following model for the 
ubiquitination of IL-5Rα (Fig. 16): Step 1, under steady state conditions, IL-5Rα is 
heavily ubiquitinated at the cell surface—by a yet to be determined ubiquitin ligase—
with faint levels of βc ubiquitination(33). Step 2, following ligand stimulation, IL-5Rα is 
drastically deubiquitinated at the cell surface, perhaps by the USP7 deubiquitinating 
enzyme (unpublished observations). At the same time, βc is heavily ubiquitinated,(33) 
most likely by the β-TrCP ubiquitin ligase (unpublished observation),  while 
constitutively associated JAK1/2 kinases are activated to phosphorylate tyrosine residues 
on both IL-5Rα and βc. Step 3, the activated tyrosine-phosphorylated IL-5R complex is 
internalized via endocytosis.  
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FIGURE 16. Working model of IL-5Rα and βc at the cell surface prior to and 
following IL-5 stimulation. Step 1, under basal conditions, IL-5Rα is highly 
ubiquitinated at the cell surface, by an unknown ubiquitin ligase, whereas βc has low 
levels of ubiquitination. Step 2, following IL-5 binding to the receptor complex, IL-5Rα 
appears to be deubiquitinated by a deubiquitinating enzyme, (perhaps USP7, 
unpublished observations), while βc is ubiquitinated by the β-TrCP ubiquitin ligase 
(unpublished observations). In addition, activation of JAK kinases results in tyrosine-
phosphorylation of both receptors’ cytoplasmic domain. Step 3, the tyrosine-activated 
receptors with heavily ubiquitinated βc and deubiquitinated IL-5Rα enter the endocytic 
pathway.   
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 Currently, this is the first report of IL-5Rα ubiquitination to date. Not only is IL-
5Rα indeed ubiquitinated, it is also surprising that IL-5Rα is ubiquitinated under steady 
state conditions. This is in stark contrast to βc, which is dependent on IL-5-induced 
ubiquitination, with marginal ubiquitination in the absence of IL-5(33). Our findings with 
IL-5Rα mutants indicate that the ubiquitination of IL-5Rα stabilizes its expression on the 
cell surface, prior to ligand stimulation, since mutants with increased basal expression of 
ubiquitination (Fig. 10) also displayed increased cell surface expression under steady 
state conditions (Fig. 9). Since βc is not ubiquitinated to the same degree as IL-5Rα 
under steady state conditions, perhaps its cell surface expression is regulated by another 
mechanism. It is highly probable that IL-5Rα and βc employ different mechanisms to 
regulate their cell surface expression, considering each receptor subunit exists 
independently of each another on the cell surface(36),  and dimerize following ligand 
simulation, a characteristic trait of many cytokine receptors(83,84). 
 Although previous studies found the cluster of three lysine residues to be crucial 
in optimizing βc ubiquitination, our data suggests that IL-5Rα lysine residues #1-4 are 
not likely involved in optimizing IL-5Rα ubiquitination. When all four lysine residues 
are mutated to arginine in our K1-4R mutant, we see IL-5Rα ubiquitination return to WT 
levels (Fig. 10). If these four lysine residues were indeed necessary for optimal IL-5Rα 
ubiquitination, we would expect to see a complete loss of ubiquitination following the 
quadruple K-to-R mutation. Thus, although both receptors are ubiquitinated, the lysine 
residues in both IL-5Rα and βc appear to have different roles in receptor ubiquitination.  
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 Although our quadruple mutant returned IL-5Rα ubiquitination to WT levels, our 
results did in fact indicate that single or double K-to-R mutations—most notably the 
K3,4R mutant— resulted in significantly increased IL-5Rα ubiquitination, relative to 
WT, under steady state conditions. Furthermore, ligand stimulation appears to strongly 
decrease WT IL-5Rα cell surface expression, while cell surface expression of the K3,4R 
mutant was only slightly reduced, indicating an impairment in IL-5-induced receptor 
internalization. Therefore, the presence of these lysine residues may have to do with the 
deubiquitination of IL-5Rα, following IL-5 stimulation, or, contrarily, they might be 
involved in regulating IL-5Rα endocytosis in steady state conditions.  
 Interestingly, the increased cell surface expression consistently seen in K3,4R 
mutant, is most likely caused by the decreased endocytosis of the mutant receptor (Fig. 
12). Considering that this mutant also had the highest expression of receptor 
ubiquitination, our findings suggest that ubiquitination stabilizes IL-5Rα on the cell 
surface, with a deubiquitination event triggering its endocytosis. These findings are in 
direct contrast to previous βc results which found that βc ubiquitination is required for its 
IL-5 induced endocytosis(33). Additionally, previous βc studies showed that the 
proteasomal degradation of the signaling, cytoplasmic domain of βc— generating the βc 
intracytoplasmic proteolysis (βIP) protein—occurs prior to signal termination via 
lysosomal degradation of the receptor complex(60). Interestingly, IP/IB analysis showed 
no presence of a truncated IL-5Rα following cytokine ligation, (Fig. 10), suggesting that 
the short cytoplasmic tail of IL-5Rα is not an adequate proteasomal substrate. Future 
studies may entail a lysosomal inhibitor, such as bafilomycin A1(85), to confirm that IL-
! 62!
5Rα signal termination requires lysosomal degradation, alongside βIP, even though a 
preceding proteasomal degradation appears to not be utilized in IL-5Rα. 
 In general, it is well supported that canonical P-X-P residues within the Box 1 
motif of Type I and II cytokine receptors are necessary for JAK kinase binding(38-40). Our 
studies revealed that a cluster of four lysine residues are also crucial for JAK kinase 
association, due to the impaired JAK binding to IL-5Rα receptor in K1-4R mutants, even 
though the P-X-P motif was still intact (Fig. 10). Additionally, this reduction of JAK 
kinase binding correlated with decreased K1-4R ubiquitination, highlighting the 
potential role of JAK kinases in optimizing receptor ubiquitination, as seen with βc(33). 
The role of JAK kinases in optimizing receptor ubiquitination was later confirmed in 
JAK1/2 knockdown studies where we saw a reduction in WT IL-5Rα ubiquitination in 
cells that lacked JAK1/2 expression (Fig. 14). However, the presence of residual 
receptor ubiquitination in JAK1/2 knockdown cells does highlight that although the 
kinases are necessary for optimal ubiquitination, additional undiscovered mechanisms of 
ubiquitination are also involved.  
 Similar findings of the role of lysine residues in JAK kinase binding to cytokine 
receptors have been made with the IFNα receptor (IFNAR1)(86,87). In an earlier report, 
researchers found that a cluster of two lysine residues were necessary for Tyk2 binding 
to IFNAR1(86). Subsequent studies found that a different cluster of lysine residues within 
IFNAR1 were critical for not only receptor ubiquitination, but also endocytosis and 
turnover(87). Interestingly, the latter study found that the ubiquitination of these three 
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lysine residues exposed a tyrosine-linear endocytic motif that, alongside receptor 
ubiquitination, was required for endocytosis.  
 Another unexpected finding in our study was the loss IL-5Rα tyrosine 
phosphorylation in K3,4R mutant cells within JAK2 overexpression studies (Fig. 15). 
This loss of tyrosine phosphorylation was not due to loss of JAK2 association with IL-
5Rα since CO-IP experiments revealed a strong association of JAK2 in IL-5Rα immune 
complexes. Thus, it is likely that the third and fourth lysine residues, Lys370 and Lys379, 
are involved with optimal JAK2 signaling. Further studies could examine the role of first 
and second lysine residues by repeating JAK2 overexpression studies with additional 
mutants, specifically K2R and K1-4R mutant cells.  
 The most striking finding of our study is the significant IL-5-dependent 
deubiquitination event of all cell surface proteins in our biotin-labeled precipitation 
assays (Fig. 12B). Furthermore, in response to cytokine stimulation, the deubiquitination 
of IL-5Rα appears to correlate with receptor internalization by endocytosis (Fig. 12A). 
Thus, we propose that following cytokine stimulation, ubiquitinated IL-5Rα is 
deubiquitinated, and this deubiquitination event triggers endocytosis of the receptor.  
 Interestingly, the K3,4R mutant had greater levels of ubiquitination in steady 
state conditions, relative to WT. Following cytokine stimulation, K3,4R mutant had a 
minimal reduction in ubiquitination and increased cell surface expression, relative to 
WT, most likely due to impaired endocytosis. Therefore, we hypothesize that the third 
and fourth lysine residues, Lys370 and Lys379, are presumably involved with the 
association and binding of deubiquitinating enzymes (DUBs) to the activated IL-5Rα. 
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The K-to-R mutation in this mutant may have prevented DUB association with the 
activated receptor, and the persistent ubiquitination of K3,4R delaying its internalization 
and, thus, increasing its residency time on the cell surface.  
 
Future Studies  
 Our most significant, and unexpected finding, was the deubiquitination event of 
all cell surface proteins following IL-5 stimulation. Considering that this 
deubiquitination event was visualized in our HEK293 cell model system, it is first 
critical to confirm a similar event under endogenous conditions. Thus, repeating the cell 
surface biotinylation assay using WT TF1 cells would be a necessary preliminary 
experiment prior to studying the possible players involved with deubiquitination.  
 Upon examination of the IL-5Rα cytoplasmic sequence, we have found a known 
deubiquitination enzyme, USP7(88), binding site at amino acid 394-398, specifically an 
AGSSE motif. Future studies could entail the use of known USP7 inhibitors, such as 
P22077(89,90), or siRNA to determine if this deubiquitinating enzyme is indeed involved 
with the major deubiquitination event. If USP7 is indeed involved with this 
deubiquitination event, then loss of USP7 activity would lead to less IL-5Ra 
deubiquitination following cytokine stimulation in cell surface biotinylation assays. 
After blocking USP7 activity, if WT begins to appear more like K3,4R following 
cytokine stimulation—i.e. more ubiquitination, delayed endocytosis, and prolonged cell 
surface expression—it is possible to potentially confirm the involvement of Lys370 and 
Lys379 in associating with DUBs, specifically USP7. 
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 Relative to WT, the K3,4R mutant had increased ubiquitination and cell surface 
expression relative to WT, both in the absence and presence of IL-5. Thus, we propose 
that the third and fourth lysine residues are perhaps involved with USP7 binding to IL-
5Rα. To elucidate this question, future studies could repeat CO-IP experiments with WT 
and K3,4R IL-5Rα, immunoprecipitating with α-IL-5Rα-antibodies and immunoblotting 
with α-USP7-antibodies. We hypothesize that if the third and fourth lysine residues are 
indeed involved with USP7 binding, a reduction in USP7 CO-IP will be seen in K3,4R 
cell lanes.  
 Additional examination of the cytoplasmic regions of both IL-3α and GM-CSFα 
shows a similar cluster of lysine residues that may serve as potential ubiquitination sites. 
Not only could the ubiquitination status of these α-chains be further studied, but also the 
possible deubiquitination event seen in IL-5Rα. Perhaps deubiquitination of the α-chains 
is a key regulatory mechanism employed by all three receptors in signal termination. 
 
Concluding Remarks  
 Although a great deal of progress has been in the functional roles of ubiquitin 
within the cell, the role of deubiquitination has become a field of interest. For instance, 
the deubiquitinating enzyme, DUB2A, was found to enhance colony-stimulating factor 3 
receptor signaling by attenuating ubiquitin-dependent lysosomal degradation of the 
receptor(91). Through the use of DUB inhibitors, such as P22077, it would be very 
interesting to further elucidate the purpose of deubiquitinating IL-5Rα. If 
deubiquitination of IL-5Rα is involved with prolonged cell signaling, perhaps inhibition 
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of its deubiquitination is a possible, more-eosinophil specific therapy against 
inflammatory disorders involving IL-5 and eosinophils. 
 Altogether, this study has provided the first indication that IL-5Rα is 
ubiquitinated. Surprisingly, ubiquitin appears to have a novel role within this receptor, 
whereby IL-5Rα ubiquitination seems to stabilize its cell surface expression, prior to 
ligand stimulation. Following IL-5 binding, a very dramatic deubiquitination event of 
IL-5Rα appears to trigger endocytosis of the receptor, entirely contrary to previous 
studies with βc(33). By far, our most significant finding is the drastic deubiquitination 
event of all cell surface proteins, which has caused us to speculate that deubiquitination 
events within the IL-5R complex may be just as important as its ubiquitination, and thus 
future studies will be focused on the deubiquitination of IL-5Rα. 
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